Literature DB >> 29240605

Platelet-Derived Growth Factor D Is a Prognostic Biomarker and Is Associated With Platinum Resistance in Epithelial Ovarian Cancer.

Mengjun Zhang, Tianbo Liu, Bairong Xia, Chunyan Yang, Siyu Hou, Wanlin Xie, Ge Lou.   

Abstract

OBJECTIVE: This study aimed to investigate whether platelet-derived growth factor D (PDGF-D) is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer, which has not been studied by others previously.
METHODS: In this study, we detected expression of PDGF-D in ovarian cancer tissues through immunohistochemistry and Western blotting. Furthermore, we analyzed the association between PDGF-D expression and clinicopathological features including prognosis in epithelial ovarian cancer. Statistical analyses were performed by using χ test, log-rank test, Cox regression test, and Kaplan-Meier method.
RESULTS: High PDGF-D expression is positively correlated with International Federation of Gynecology and Obstetrics stage (P < 0.001), histologic grade (P < 0.001), lymph node metastasis (P = 0.022), and poor prognosis (P < 0.001). Platelet-derived growth factor D in platinum-resistant cases is overexpressed compared with that in platinum-sensitive cases (P < 0.001). Obstetrics stage (P = 0.029) and PDGF-D overexpression (P < 0.001) are independently correlated with platinum resistance.
CONCLUSIONS: Our study indicates that PDGF-D overexpression is an independent predictor of platinum-based chemotherapy resistance and that it may also be a potential biomarker for targeted therapy and poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29240605     DOI: 10.1097/IGC.0000000000001171

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment.

Authors:  William L Hwang; Karthik A Jagadeesh; Jimmy A Guo; Hannah I Hoffman; Payman Yadollahpour; Jason W Reeves; Rahul Mohan; Eugene Drokhlyansky; Nicholas Van Wittenberghe; Orr Ashenberg; Samouil L Farhi; Denis Schapiro; Prajan Divakar; Eric Miller; Daniel R Zollinger; George Eng; Jason M Schenkel; Jennifer Su; Carina Shiau; Patrick Yu; William A Freed-Pastor; Domenic Abbondanza; Arnav Mehta; Joshua Gould; Conner Lambden; Caroline B M Porter; Alexander Tsankov; Danielle Dionne; Julia Waldman; Michael S Cuoco; Lan Nguyen; Toni Delorey; Devan Phillips; Jaimie L Barth; Marina Kem; Clifton Rodrigues; Debora Ciprani; Jorge Roldan; Piotr Zelga; Vjola Jorgji; Jonathan H Chen; Zackery Ely; Daniel Zhao; Kit Fuhrman; Robin Fropf; Joseph M Beechem; Jay S Loeffler; David P Ryan; Colin D Weekes; Cristina R Ferrone; Motaz Qadan; Martin J Aryee; Rakesh K Jain; Donna S Neuberg; Jennifer Y Wo; Theodore S Hong; Ramnik Xavier; Andrew J Aguirre; Orit Rozenblatt-Rosen; Mari Mino-Kenudson; Carlos Fernandez-Del Castillo; Andrew S Liss; David T Ting; Tyler Jacks; Aviv Regev
Journal:  Nat Genet       Date:  2022-07-28       Impact factor: 41.307

2.  The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.

Authors:  Lijiang He; Hainan Yang; Jingshan Huang
Journal:  BMC Cancer       Date:  2021-05-21       Impact factor: 4.430

3.  Forecasting early onset diminished ovarian reserve for young reproductive age women.

Authors:  Blair R McCallie; Mary Haywood; Michelle M Denomme; Rachel Makloski; Jason C Parks; Darren K Griffin; William B Schoolcraft; Mandy G Katz-Jaffe
Journal:  J Assist Reprod Genet       Date:  2021-03-30       Impact factor: 3.357

4.  Identification of Immune-Related Breast Cancer Chemotherapy Resistance Genes via Bioinformatics Approaches.

Authors:  Yabing Du; Yikai Han; Xin Wang; Huanrong Wang; Yanhong Qu; Kaiyuan Guo; Wang Ma; Lijun Fu
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

Review 5.  Targeting the Microenvironment in High Grade Serous Ovarian Cancer.

Authors:  Nkechiyere G Nwani; Livia E Sima; Wilberto Nieves-Neira; Daniela Matei
Journal:  Cancers (Basel)       Date:  2018-08-10       Impact factor: 6.639

6.  PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.

Authors:  Jia Jin; Leiping Wang; Zhonghua Tao; Jian Zhang; Fangfang Lv; Junning Cao; Xichun Hu
Journal:  Mol Med Rep       Date:  2020-03-12       Impact factor: 2.952

7.  Overexpression of Platelet-Derived Growth Factor and Its Receptor Are Correlated with Oral Tumorigenesis and Poor Prognosis in Oral Squamous Cell Carcinoma.

Authors:  Li-Han Lin; Jiun-Sheng Lin; Cheng-Chieh Yang; Hui-Wen Cheng; Kuo-Wei Chang; Chung-Ji Liu
Journal:  Int J Mol Sci       Date:  2020-03-29       Impact factor: 5.923

8.  Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer.

Authors:  Wangang Gong; Yongyi Chen; Yingli Zhang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.